Developer docs
API playgroundTry for free, no card

Search company profiles

Neopenda

Full company profile

uuid0000ptv

Namestring
Neopenda
Legal namestring
Neopenda, PBC
Websiteurl
neopenda.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Neopenda, PBC is a Chicago-headquartered public benefit corporation founded in 2015 at Columbia University that designs, manufactures, and sells the neoGuard™, a clinical-grade wearable vital signs monitor aimed at resource-constrained health facilities in emerging markets. The device continuously measures four vital signs—pulse rate, respiratory rate, SpO2 (blood oxygen saturation), and temperature—in a single wearable form factor and delivers real-time alerts to clinicians, addressing conditions including power instability, intermittent internet, space constraints, and limited spare-part availability. Neopenda holds ISO 13485 certification and CE Mark approval, and its clinical accuracy has been validated in peer-reviewed publications including Frontiers in Digital Health. The company reports more than 45 hospital customers across Kenya, Uganda, and Ghana that purchase neoGuard directly with their own operating budgets, making the business model a B2B hardware sales motion complemented by a community investment capital raise via Wefunder.

Neopenda sells a single flagship product line (neoGuard) through direct field sales to hospitals and neonatal care units, with primary use cases centered on neonatal monitoring where 2.6 million annual first-month neonatal deaths—98% in the developing world and 80% preventable—define the addressable need. Distribution is concentrated in East and West Africa, with operational support in Nairobi and named deployments at facilities such as Tabaka Mission Hospital in Kenya, Mulago Hospital and RUNH in Uganda, and tertiary hospitals in Southwest Nigeria. The company is led by co-founders Sona Shah (CEO) and Teresa Cauvel (CTO), with a lean team of roughly 10-15 staff spanning embedded and Android engineering, supply chain and quality, customer success, and sales.

Capitalization totals over $6 million across a mix of grants, convertible notes, angel/venture funding, and community investment, with investors including Axel Johnson, Sunu Capital, Villgro Kenya, 54 Collective, Sorenson Impact Foundation, Springhood, Connetic Ventures, and Assiduity Capital. Recent strategic moves include a January 2024 SEC Form D exempt offering of up to $1.5M, an ongoing Wefunder community round, and 2024 inclusion in the WHO Compendium of Innovative Health Technologies for Low-Resource Settings and the UNITAID Oxygen Innovation Landscape, which together support procurement credibility with ministries of health and global health agencies.

Short descriptiontext

Neopenda is a Chicago-based public benefit corporation that designs and sells neoGuard, a clinical-grade wearable vital signs monitor for neonatal and patient monitoring in resource-constrained hospitals across Kenya, Uganda, and Ghana. It serves more than 45 hospitals through direct B2B hardware sales.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersChicago, United States
HQ citystring
Chicago
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
wearable vital signs monitor, neonatal care devices, clinical-grade patient monitoring, medical devices emerging markets, continuous vital sign monitoring
Industry2 codes
PRIMARYHLAHACAF
Maternal, Fetal & Neonatal Monitoring (CTG, Infant Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLAHACAA
Vital Signs Monitoring (Multi-parameter, Spot-Check & Continuous)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
NAICS code3 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing33451
  • Medical Equipment and Supplies Manufacturing3391
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Medical Devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1neoGuard Device Sales
TypeHardware Sales
Description

Sale of neoGuard vital signs monitors directly to hospitals and healthcare facilities in emerging markets. Hardware sales model with direct B2B purchasing by hospitals.

neopenda.com
2Convertible Note Financing
TypeOne Time License
Description

SEC filing indicates $1.5 million exempt securities offering with $700,000 already sold. Community investment round through Wefunder allows investment starting at $100.

sec.gov
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Community Investment Round
ModelOtherBilling cadenceOne time
Notes

Minimum investment of $100 through Wefunder platform. Community round offering early access and favorable investment terms.

neopenda.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1neoGuard
Description

A clinical-grade vital signs monitor designed for resource-constrained health facilities. The 4-in-1 device continuously measures pulse rate, respiratory rate, SpO2, and temperature, providing critical data in real-time.

neopenda.com
Core offering1 text field

Neopenda designs, manufactures, and sells neoGuard™, a clinical-grade wearable vital signs monitor for resource-constrained health facilities. The device continuously measures pulse rate, respiratory rate, SpO2, and temperature in a single wearable and provides real-time alerts to clinicians. It is sold directly to hospitals and neonatal care units in emerging markets including Kenya, Uganda, and Ghana.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Neopenda offers a single flagship product: neoGuard™, a clinical-grade wearable vital signs monitor. NeoGuard™ is designed specifically for resource-constrained health facilities in emerging markets and continuously measures four vital signs (pulse rate, respiratory rate, SpO2, and temperature) with real-time alerting capabilities. The company operates as a medical device manufacturer providing this hardware product directly to hospitals across Kenya, Uganda, and Ghana.

Product and service1 record
1neoGuard™ Vital Signs Monitor
CategoryMedical Devices - Wearable Patient Monitoring
Description

Clinical-grade wearable vital signs monitor designed for resource-constrained health facilities. Continuously measures pulse rate, respiratory rate, SpO2 (blood oxygen saturation), and temperature in a single wearable device, and provides real-time alerts to clinicians when patient vital signs deteriorate. ISO 13485 certified and CE Mark approved. Sold directly to hospitals and neonatal care units in Kenya, Uganda, and Ghana.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeGTM or Marketing Partner
Description

Platform partnership for community investment rounds. Enables individual investors to invest in Neopenda starting from $100, providing accessible investment opportunities and building community ownership.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Featured in WHO compendium of innovative health technologies for low-resource settings 2024, providing international validation and visibility for neoGuard technology.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Featured in UNITAID Oxygen Innovation Landscape 2024, recognizing the product's contribution to medical oxygen access in low-resource settings.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Won MIT Solve Challenge 2018 Frontlines of Health, providing mentorship, network access, and credibility as a Solver team in the global health tech ecosystem.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Willo Brock, SVP of External Affairs at TB Alliance, serves on Neopenda's Board of Advisors, providing strategic guidance on global health issues.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Neopenda was founded at Columbia University in 2015. Dr. Aaron Kyle (faculty) and Katherine Reuther (Co-Director of Columbia Biomedical Accelerator) serve on the Board of Advisors.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Dr. Peter Waiswa, researcher and lecturer, serves on Neopenda's Board of Advisors, providing expertise in public health in East Africa.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Organization whose image courtesy credit appears on Neopenda's website, indicating partnership in the efficiency and access to healthcare technology space.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Gradian builds and distributes anesthesia machines and other medical devices designed for low-resource hospitals in Africa and Asia. Like Neopenda, Gradian engineers hardware around the constraints of power instability, technician scarcity, and budget pressure in emerging markets.

TypeBroad incumbent
Description

Masimo is a global leader in pulse oximetry and patient monitoring technology, with a large installed base in hospitals worldwide. It competes indirectly with neoGuard on SpO2 and respiratory rate monitoring and represents the scale incumbent Neopenda must differentiate against on cost and ruggedization.

TypeBroad incumbent
Description

Philips offers a broad portfolio of multi-parameter vital signs monitors and ICU solutions used in hospitals globally. It is the dominant incumbent in continuous patient monitoring and overlaps with neoGuard on use cases such as neonatal and general ward monitoring.

TypeBroad incumbent
Description

GE HealthCare provides multi-parameter patient monitors, including neonatal and ICU solutions sold to hospitals worldwide. It is a broad incumbent competitor with much larger scale but products typically priced and engineered for well-resourced facilities.

TypeBroad incumbent
Description

Medtronic offers patient monitoring and vital signs products as part of a broader medical device portfolio. Its monitoring business competes with neoGuard in hospital settings while also serving far larger therapeutic categories.

TypeDirect peer
Description

Nonin specializes in pulse oximetry and capnography sensors, including fingertip and wearable form factors used in clinical and home settings. It overlaps directly with neoGuard's SpO2 and respiratory rate monitoring capabilities.

TypeDirect peer
Description

Laerdal Global Health focuses on affordable, ruggedized neonatal and maternal health solutions for low-resource settings, including training and resuscitation devices. It shares Neopenda's emerging-market neonatal mission and donor-funded distribution model.

TypeEmerging player
Description

EarlySense provides contact-free continuous patient monitoring sensors for hospital wards. It overlaps with neoGuard in continuous vital signs monitoring but is focused on general medical-surgical wards in higher-acuity markets.

TypeEmerging player
Description

BioIntelliSense offers continuous multi-parameter wearable monitoring with remote data capture for clinical and post-acute settings. It shares neoGuard's continuous multi-vital-signs approach but targets U.S. and developed-market customers.

10Biofourmis
TypeEmerging player
Description

Biofourmis provides continuous remote patient monitoring and analytics, including wearable biosensors and AI-driven alerting. It competes in the broader continuous vital signs monitoring category but is more software- and analytics-led than Neopenda's hardware-first approach.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds17 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Neopenda

Medical Devicesneopenda.com

Neopenda is a Chicago-based public benefit corporation that designs and sells neoGuard, a clinical-grade wearable vital signs monitor for neonatal and patient monitoring in resource-constrained hospitals across Kenya, Uganda, and Ghana. It serves more than 45 hospitals through direct B2B hardware sales.

What Neopenda does

Neopenda, PBC is a Chicago-headquartered public benefit corporation founded in 2015 at Columbia University that designs, manufactures, and sells the neoGuard™, a clinical-grade wearable vital signs monitor aimed at resource-constrained health facilities in emerging markets. The device continuously measures four vital signs—pulse rate, respiratory rate, SpO2 (blood oxygen saturation), and temperature—in a single wearable form factor and delivers real-time alerts to clinicians, addressing conditions including power instability, intermittent internet, space constraints, and limited spare-part availability. Neopenda holds ISO 13485 certification and CE Mark approval, and its clinical accuracy has been validated in peer-reviewed publications including Frontiers in Digital Health. The company reports more than 45 hospital customers across Kenya, Uganda, and Ghana that purchase neoGuard directly with their own operating budgets, making the business model a B2B hardware sales motion complemented by a community investment capital raise via Wefunder.

Neopenda sells a single flagship product line (neoGuard) through direct field sales to hospitals and neonatal care units, with primary use cases centered on neonatal monitoring where 2.6 million annual first-month neonatal deaths—98% in the developing world and 80% preventable—define the addressable need. Distribution is concentrated in East and West Africa, with operational support in Nairobi and named deployments at facilities such as Tabaka Mission Hospital in Kenya, Mulago Hospital and RUNH in Uganda, and tertiary hospitals in Southwest Nigeria. The company is led by co-founders Sona Shah (CEO) and Teresa Cauvel (CTO), with a lean team of roughly 10-15 staff spanning embedded and Android engineering, supply chain and quality, customer success, and sales.

Capitalization totals over $6 million across a mix of grants, convertible notes, angel/venture funding, and community investment, with investors including Axel Johnson, Sunu Capital, Villgro Kenya, 54 Collective, Sorenson Impact Foundation, Springhood, Connetic Ventures, and Assiduity Capital. Recent strategic moves include a January 2024 SEC Form D exempt offering of up to $1.5M, an ongoing Wefunder community round, and 2024 inclusion in the WHO Compendium of Innovative Health Technologies for Low-Resource Settings and the UNITAID Oxygen Innovation Landscape, which together support procurement credibility with ministries of health and global health agencies.

Neopenda firmographics

Firmographics
Name
Neopenda
Legal name
Neopenda, PBC
Website
https://neopenda.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Neopenda is a Chicago-based public benefit corporation that designs and sells neoGuard, a clinical-grade wearable vital signs monitor for neonatal and patient monitoring in resource-constrained hospitals across Kenya, Uganda, and Ghana. It serves more than 45 hospitals through direct B2B hardware sales.
Ownership category
akta.pro rank

Neopenda industry classification

Industry
Product category
Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451), Medical Equipment and Supplies Manufacturing (3391)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHACAF
Maternal, Fetal & Neonatal Monitoring (CTG, Infant Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLAHACAA
Vital Signs Monitoring (Multi-parameter, Spot-Check & Continuous)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics

Keywords

  • Wearable vital signs monitor
  • Neonatal care devices
  • Clinical-grade patient monitoring
  • Medical devices emerging markets
  • Continuous vital sign monitoring

Where Neopenda is headquartered

Location

Headquarters

HQ city
Chicago
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Neopenda business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. neoGuard Device Sales: Sale of neoGuard vital signs monitors directly to hospitals and healthcare facilities in emerging markets. Hardware sales model with direct B2B purchasing by hospitals.
  2. Convertible Note Financing: SEC filing indicates $1.5 million exempt securities offering with $700,000 already sold. Community investment round through Wefunder allows investment starting at $100.

Pricing tiers

ModelBillingPrice
OtherOne timeCommunity Investment Round

Go-to-market motion2 records

Distribution channels2 records

Marketing channels8 records

Neopenda product offering

Product offering

Core offering

Neopenda designs, manufactures, and sells neoGuard™, a clinical-grade wearable vital signs monitor for resource-constrained health facilities. The device continuously measures pulse rate, respiratory rate, SpO2, and temperature in a single wearable and provides real-time alerts to clinicians. It is sold directly to hospitals and neonatal care units in emerging markets including Kenya, Uganda, and Ghana.

Product overview

Neopenda offers a single flagship product: neoGuard™, a clinical-grade wearable vital signs monitor. NeoGuard™ is designed specifically for resource-constrained health facilities in emerging markets and continuously measures four vital signs (pulse rate, respiratory rate, SpO2, and temperature) with real-time alerting capabilities. The company operates as a medical device manufacturer providing this hardware product directly to hospitals across Kenya, Uganda, and Ghana.

Differentiator

Problem solved

Functional benefit

Brands

  • neoGuard: A clinical-grade vital signs monitor designed for resource-constrained health facilities. The 4-in-1 device continuously measures pulse rate, respiratory rate, SpO2, and temperature, providing critical data in real-time.

Products and services

  • neoGuard™ Vital Signs Monitor Clinical-grade wearable vital signs monitor designed for resource-constrained health facilities. Continuously measures pulse rate, respiratory rate, SpO2 (blood oxygen saturation), and temperature in a single wearable device, and provides real-time alerts to clinicians when patient vital signs deteriorate. ISO 13485 certified and CE Mark approved. Sold directly to hospitals and neonatal care units in Kenya, Uganda, and Ghana.

Companies that use Neopenda

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles1 record

Neopenda technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Neopenda partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core, flagship and minor.

  • WefundercoreGTM or Marketing PartnerPlatform partnership for community investment rounds. Enables individual investors to invest in Neopenda starting from $100, providing accessible investment opportunities and building community ownership.
  • World Health Organization (WHO)flagshipStrategic or Co-development PartnerFeatured in WHO compendium of innovative health technologies for low-resource settings 2024, providing international validation and visibility for neoGuard technology.
  • UNITAIDcoreStrategic or Co-development PartnerFeatured in UNITAID Oxygen Innovation Landscape 2024, recognizing the product's contribution to medical oxygen access in low-resource settings.
  • MIT SolvecoreStrategic or Co-development PartnerWon MIT Solve Challenge 2018 Frontlines of Health, providing mentorship, network access, and credibility as a Solver team in the global health tech ecosystem.
  • TB AllianceminorStrategic or Co-development PartnerWillo Brock, SVP of External Affairs at TB Alliance, serves on Neopenda's Board of Advisors, providing strategic guidance on global health issues.
  • Columbia UniversitycoreStrategic or Co-development PartnerNeopenda was founded at Columbia University in 2015. Dr. Aaron Kyle (faculty) and Katherine Reuther (Co-Director of Columbia Biomedical Accelerator) serve on the Board of Advisors.
  • Makerere University School of Public HealthcoreStrategic or Co-development PartnerDr. Peter Waiswa, researcher and lecturer, serves on Neopenda's Board of Advisors, providing expertise in public health in East Africa.
  • Efficiency for AccessminorStrategic or Co-development PartnerOrganization whose image courtesy credit appears on Neopenda's website, indicating partnership in the efficiency and access to healthcare technology space.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Neopenda competitors and assessment

Company assessment

Direct peers

  • Gradian Health Systems: Gradian builds and distributes anesthesia machines and other medical devices designed for low-resource hospitals in Africa and Asia. Like Neopenda, Gradian engineers hardware around the constraints of power instability, technician scarcity, and budget pressure in emerging markets.
  • Nonin Medical: Nonin specializes in pulse oximetry and capnography sensors, including fingertip and wearable form factors used in clinical and home settings. It overlaps directly with neoGuard's SpO2 and respiratory rate monitoring capabilities.
  • Laerdal Global Health: Laerdal Global Health focuses on affordable, ruggedized neonatal and maternal health solutions for low-resource settings, including training and resuscitation devices. It shares Neopenda's emerging-market neonatal mission and donor-funded distribution model.

Broad incumbents

  • Masimo: Masimo is a global leader in pulse oximetry and patient monitoring technology, with a large installed base in hospitals worldwide. It competes indirectly with neoGuard on SpO2 and respiratory rate monitoring and represents the scale incumbent Neopenda must differentiate against on cost and ruggedization.
  • Philips Patient Monitoring: Philips offers a broad portfolio of multi-parameter vital signs monitors and ICU solutions used in hospitals globally. It is the dominant incumbent in continuous patient monitoring and overlaps with neoGuard on use cases such as neonatal and general ward monitoring.
  • GE HealthCare Patient Monitoring: GE HealthCare provides multi-parameter patient monitors, including neonatal and ICU solutions sold to hospitals worldwide. It is a broad incumbent competitor with much larger scale but products typically priced and engineered for well-resourced facilities.
  • Medtronic (Patient Monitoring): Medtronic offers patient monitoring and vital signs products as part of a broader medical device portfolio. Its monitoring business competes with neoGuard in hospital settings while also serving far larger therapeutic categories.

Emerging players

  • EarlySense: EarlySense provides contact-free continuous patient monitoring sensors for hospital wards. It overlaps with neoGuard in continuous vital signs monitoring but is focused on general medical-surgical wards in higher-acuity markets.
  • BioIntelliSense: BioIntelliSense offers continuous multi-parameter wearable monitoring with remote data capture for clinical and post-acute settings. It shares neoGuard's continuous multi-vital-signs approach but targets U.S. and developed-market customers.
  • Biofourmis: Biofourmis provides continuous remote patient monitoring and analytics, including wearable biosensors and AI-driven alerting. It competes in the broader continuous vital signs monitoring category but is more software- and analytics-led than Neopenda's hardware-first approach.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Neopenda social profiles

Digital presence

Neopenda compliance and trust

Trust signal

Compliance2 records

Neopenda financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Neopenda leadership team

Management profile

Number of profiles

Profiles8 records

Neopenda funding detail

Funding detail

Funding overview

Funding rounds17 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Neopenda M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neopenda

What does Neopenda do?

Neopenda designs, manufactures, and sells neoGuard™, a clinical-grade wearable vital signs monitor for resource-constrained health facilities. The device continuously measures pulse rate, respiratory rate, SpO2, and temperature in a single wearable and provides real-time alerts to clinicians. It is sold directly to hospitals and neonatal care units in emerging markets including Kenya, Uganda, and Ghana.

Is Neopenda a public or private company?

Neopenda is a private company. It is classified as venture growth investor backed and is currently operating.

When was Neopenda founded?

Neopenda was founded in 2015. It employs 11 to 50 people.

Where is Neopenda based?

Neopenda is headquartered in Chicago, United States, in the North America region.

How does Neopenda make money?

Two revenue lines are on record. neoGuard Device Sales are the primary driver. The others are convertible Note Financing.

Who are Neopenda's main competitors?

Direct peers on record are Gradian Health Systems, Nonin Medical and Laerdal Global Health. Broad incumbents are Masimo, Philips Patient Monitoring, GE HealthCare Patient Monitoring and Medtronic (Patient Monitoring). Emerging players are EarlySense, BioIntelliSense and Biofourmis.

Does Neopenda have an API?

No public API is recorded for Neopenda.

What industry is Neopenda in?

Neopenda's product category is Medical Devices. Its primary akta.pro industry code is HLAHACAF, Maternal, Fetal & Neonatal Monitoring (CTG, Infant Wearables), with a secondary code of HLAHACAA, Vital Signs Monitoring (Multi-parameter, Spot-Check & Continuous). Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Columbia EngineeringSigns of LifeSona Shah and Teresa Cauvel founded Neopenda, a startup developing a wearable monitor for newborns to track vital signs in under-resourced hospitals. The company has secured significant funding through university competitions, accelerators, and innovation challenges, including prizes from Cisco and Vodafone. They plan to begin clinical studies in New York and Uganda with the goal of selling devices by early 2018.SecSEC FORM DNeopenda, PBC, a biotechnology company incorporated in Delaware, has filed a Form D with the Securities and Exchange Commission to offer securities totaling $1,500,000. The filing indicates that $700,000 has already been sold, leaving $800,000 remaining to be sold, with a minimum investment of $10,000 required from investors.SecSEC FORM DNeopenda, PBC filed a Form D with the SEC for an exempt offering of securities under Rule 506(b) with a total offering amount of $1.5 million. The filing indicates that $500,000 has been sold to four investors as of August 2022, with a minimum investment threshold of $50,000.ButlertechnologiesNew Wearable Technology: 6 Best Smart Clothing Items of 2022Butler Technologies, Inc. published a roundup of six smart clothing items for 2022, highlighting products from Levi’s, Sensoria, Neviano, Nadi X, Under Armour, and Neopenda that integrate biometric sensors and connectivity features. The article details how these garments utilize printed electronics to monitor health metrics, track activity, and enhance user safety through technologies like GPS and heart rate monitoring.FrontiersDeveloping Medical Technologies for Low-Resource Settings: Lessons From a Wireless Wearable Vital Signs Monitor–neoGuardNeopenda, PBC details the development and commercialization journey of neoGuard, a wireless wearable vital signs monitor designed for low-resource settings. The company successfully navigated clinical validation in the US and Uganda, obtained CE marking under EU MDR regulations, and launched the product in Kenya and Uganda through local distributors.FoundersfactoryNeopenda is a startup from FFA's healthtech portfolioNeopenda developed the neoGuardTM wearable vital signs monitor to improve patient care in resource-constrained hospitals, especially for neonates and recently adapted for adults to aid COVID-19 response. The device continuously measures vital signs and alerts health workers to medical distress, with efforts to expand distribution in East Africa and Nigeria.Villgro AfricaNeopenda Graduates from Villgro Africa's PortfolioNeopenda, a Ugandan healthtech organization, has completed Villgro Africa’s one-year incubation program, transitioning from research and development to commercial launch. Supported by the incubator, Neopenda secured its first contract and generated initial revenue despite supply chain disruptions caused by the pandemic. The company is now seeking strategic partners to facilitate its expansion into new countries.PR NewswireChicago Medtech Startup, Neopenda, Announces New Round of Convertible Note FinancingNeopenda, a Chicago-based public benefit corporation, announced a new round of convertible note financing supported by Assiduity Capital and Sorenson Impact Foundation, along with receiving CE Mark approval for its neoGuard device. The company aims to expand its impact in healthcare by distributing the neoGuard, a wearable monitor for critically ill patients, particularly in low-resource areas. With $1.4 million in funding secured, Neopenda plans to grow its team to enhance its operational capacity.Disrupt-africaUganda e-health startup Neopenda raises $1.04m funding round – Old Disrupt AfricaUganda-based e-health startup Neopenda closed a $1.04 million seed round led by Axel Johnson Inc, with participation from SUNU Capital and angels. The funding will support manufacturing, team growth, and expanding clinical pilots. Its wearable device monitors pulse, respiratory rate, blood oxygen, and temperature.WeeTrackerUganda-Focused Neopenda Raises USD 300 K From Its Crowdfunding Equity CampaignNeopenda, a Chicago-based public benefit corporation focusing on Uganda, has completed a crowdfunding equity campaign, raising over USD 300,000 from 703 investors. The campaign, which exceeded its original goal of USD 275,000, marks a significant step towards the company's commercialization of its wearable neonatal vitals monitor, aimed at reducing infant mortality in low-resource regions. Neopenda plans to leverage the funds to achieve key milestones and bring the product to East African markets in 2019.